AstraZeneca (AZN) has released an update.
AstraZeneca PLC has announced the grant of ordinary shares to CEO Pascal Soriot as part of the AstraZeneca Performance Share Plan (AZPSP), following the rules approved by shareholders at their 2024 Annual General Meeting. These shares, tied to performance measures over a three-year period and subject to a two-year holding period post-performance, are set to vest five years after the grant date. The company emphasizes its global presence in the biopharmaceutical sector, with a focus on prescription medicines in several key health areas.
For further insights into AZN stock, check out TipRanks’ Stock Analysis page.
